Lupin has informed about submission of a Press Release as regards AbbVie Inc. having licensed the company’s MALTI (Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein I) inhibitor program through which AbbVie gains exclusive global rights to develop and commercialize the company’s MALTI inhibitors. This disclosure is under pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.